Dive Brief:
- Endologix said Tuesday it has bought a device for removing clots from peripheral arteries from Surmodics for an undisclosed amount.
- The product, Pounce, is a catheter system for the mechanical, nonsurgical removal of thrombi and emboli, types of vascular blockages including clots.
- Surmodics, which received 510(k) clearance for Pounce in 2020, has divested the device months after being acquired by a private equity company for $627 million.
Dive Insight:
Physicians use Pounce’s catheter to deliver two nitinol self‐expanding baskets to the far side of the clot, and a funnel to the near side of the clot. As the baskets are pulled back along the artery, they push the clot into the funnel. Once the clot is in the funnel, the physician locks the device to ensure the baskets stay in place as the device is removed, carrying the thrombus or embolus with it.
Surmodics named Nexgen Medical Systems’ peripheral mechanical retrieval device and expandable catheter as predicates when it filed for a 510(k). The company subsequently received 510(k) clearance for other Pounce products, such as a larger device that the Food and Drug Administration cleared in 2024.
Having established a direct sales force and started commercialization in 2022, Surmodics began to see “modest, but meaningful and growing revenue” associated with the product that year. Growing Pounce sales contributed to the $45.6 million in medical device product revenue that Surmodics reported in 2024, its last full financial year as a public company.
Pounce sales continued to grow over the first nine months of 2025. However, the growth only partly offset financial pressures including a $6.4 million drop in sales of another device.
Endologix will market Pounce to vascular interventionists who already use its Detour, Alto and AFX2 platforms. Detour is a treatment for peripheral artery disease, while Alto and AFX2 are, respectively, a stent graft and endovascular system for treating abdominal aortic aneurysms.
Endologix said in the deal announcement that a core group of Surmodics team members supporting Pounce will join the company as part of the transaction.
